Seaport Therapeutics
- Company typePublic
- Founded2024
- HeadquartersBoston, United States
- Headcount51–100
- GTM typeB2B
- OfferingHardware or Manufacturing
Seaport Therapeutics firmographics
Firmographics- Name
- Seaport Therapeutics
- Legal name
- Seaport Therapeutics, Inc.
- Website
- https://seaporttx.com
- Company type
- Public
- Founded year
- 2024
- Operating status
- Operating
- Headcount range
- 51–100 employees
- Ownership category
- akta.pro rank
Seaport Therapeutics industry classification
Industry- Product category
- Clinical-stage neuropsychiatric pharmaceuticals
- NAICS
- Scientific Research and Development Services (5417)
- SIC
- Pharmaceutical Preparations (2834)
- akta.pro primary industry
- Rare Neurology & Neurodegenerative Disorder Therapies (HLAIAIAD)
Keywords
Where Seaport Therapeutics is headquartered
LocationHeadquarters
- HQ city
- Boston
- HQ country
- United States
- HQ region
- North America
Offices1 record
Markets served
Seaport Therapeutics business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Operations, Marketing or Sales, Infrastructure
Revenue model
- Pharmaceutical Product Sales: Pre-revenue clinical-stage company. Once regulatory approval is obtained, the company plans to commercialize its neuropsychiatric drug candidates through traditional pharmaceutical sales and distribution channels. The company has not yet generated revenue from product sales.
Go-to-market motion1 record
Distribution channels1 record
Marketing channels4 records
Seaport Therapeutics product offering
Product offeringCore offering
Seaport Therapeutics is a clinical-stage biopharmaceutical company developing oral neuropsychiatric medicines using its proprietary Glyph™ lymphatic-targeting prodrug platform. The company's lead programs are GlyphAllo (SPT-300) for major depressive disorder and GlyphAgo (SPT-320) for generalized anxiety disorder, with additional pipeline candidates in pre-clinical development. Products are investigational, have not yet received regulatory approval, and are not generating revenue.
Product overview
Seaport Therapeutics is a clinical-stage biopharmaceutical company developing a pipeline of novel neuropsychiatric medicines using its proprietary Glyph™ lymphatic-targeting prodrug platform. The Glyph platform enables oral drug administration via intestinal lymphatic transport, bypassing first-pass liver metabolism to enhance bioavailability and reduce side effects. The company advances three lead therapeutic candidates: GlyphAllo™ (SPT-300) for Major Depressive Disorder in Phase 2b, GlyphAgo™ (SPT-320) for Generalized Anxiety Disorder in Phase 2b, and Glyph2BLSD™ (SPT-348) for multiple neuropsychiatric indications in pre-clinical development. Additional programs include GlyphCele™ for metabolic disease and pancreatic cancer, and GlyphCBD™ for epilepsy. The platform was originally developed at Monash University and exclusively licensed to Seaport.
Differentiator
Problem solved
Functional benefit
Brands
- GlyphAllo (SPT-300): Novel oral prodrug of allopregnanolone for major depressive disorder (MDD)
- GlyphAgo (SPT-320)
- Glyph2BLSD (SPT-348)
- GlyphCele
Products and services
- GlyphAllo™ (SPT-300) Investigational oral prodrug of allopregnanolone in development for Major Depressive Disorder (with or without anxious distress), leveraging the Glyph lymphatic-targeting platform to enable oral dosing and replace IV infusion; demonstrated approximately 9x greater allopregnanolone exposure than previously reported with oral allopregnanolone and significant reduction of salivary cortisol vs placebo (p=0.0001) in Phase 2a.
- GlyphAgo™ (SPT-320) Investigational oral prodrug of agomelatine in development for Generalized Anxiety Disorder, designed via the Glyph platform to avoid first-pass liver metabolism; demonstrated 6.8-fold increase in bioavailability and 10-fold reduction in pharmacokinetic variability (p<0.0001) vs unmodified agomelatine, with the potential to eliminate liver function testing requirements.
- Glyph2BLSD™ (SPT-348) Pre-clinical oral prodrug of 2-bromo-LSD, a non-hallucinogenic neuroplastogen being developed for depressive disorders, PTSD, and headache disorders with potential for outpatient and repeat dosing.
- GlyphCele™ (GlyphCelecoxib) Investigational Glyph oral prodrug of celecoxib designed to target the lymphatic system, reduce systemic exposure, and restore normal lymphatic function; being developed for metabolic disease and pancreatic cancer in collaboration with ARPA-H under the GLIDE program.
- GlyphCBD™ (SPT-310) Pre-clinical oral prodrug of CBD being developed for epilepsy/seizure disorders, with enhanced bioavailability and reduced hepatotoxicity risk compared with conventional CBD formulations.
Quantifiable outcome
- GlyphAgo demonstrated 6.8-fold increase in bioavailability vs unmodified agomelatine (90% CI: 4.7-10.0x)
- +3 more outcomes
Companies that use Seaport Therapeutics
Customer profileSegments2 records
Ideal customer profiles2 records
Seaport Therapeutics technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature5 records
Seaport Therapeutics partnerships and signals
Strategic signalPartnerships
One partnership is on record.
- Monash Institute of Pharmaceutical Sciences (MIPS)coreCollaboration with Monash University for the development of GlyphCele and continued advancement of the Glyph platform. Christopher Porter, Ph.D., Director of MIPS, is the original co-inventor of Glyph technology. The collaboration leverages decades of scientific progress in lymphatic physiology and therapeutic transport research.
Scale indicators7 records
Recent moves8 records
Expansion highlights6 records
Seaport Therapeutics competitors and assessment
Company assessmentDirect peers
- Karuna Therapeutics: CNS-focused biopharma co-founded by Seaport's current leadership (Daphne Zohar, Steven Paul) that developed Cobenfy (KarXT/xanomeline-trospium) for schizophrenia; acquired by Bristol Myers Squibb for $14B. Same founders and playbook make it the most directly comparable peer, despite now being part of BMS.
- Sage Therapeutics: Clinical-stage CNS biopharma that developed Zurzuvae (zuranolone) for postpartum depression and MDD with Biogen. Directly comparable as a CNS-focused company targeting depression with novel neuroactive steroid mechanisms and facing similar clinical and commercial dynamics.
- Axsome Therapeutics: Commercial-stage CNS biopharma that developed and launched Auvelity (dextromethorphan-bupropion) for major depressive disorder. Closely comparable given its CNS focus, MDD positioning, and similar pursuit of differentiated oral therapies in neuropsychiatry.
- Intra-Cellular Therapies: CNS biopharma that developed and commercialized Caplyta (lumateperone) for schizophrenia, bipolar depression, and MDD adjunctive treatment, generating $1.5B+ in sales before being acquired by Johnson & Johnson for ~$14.6B. Direct CNS peer; Sharon Mates (now Seaport board member) led this company.
Emerging players
- Neumora Therapeutics: Clinical-stage biopharma developing precision medicines for neuropsychiatric disorders, including MDD. Comparable as a similarly-sized, well-funded CNS-focused biotech pursuing differentiated mechanisms in depression and adjacent indications.
- Praxis Precision Medicines: Clinical-stage biopharma developing therapies for CNS disorders including depression and epilepsy. Comparable as a small-cap CNS-focused peer with a similarly staged pipeline and platform-based approach to neurological indications.
- Compass Pathways: Clinical-stage mental health company developing psilocybin therapy for treatment-resistant depression and other psychiatric conditions. Comparable as a publicly traded neuropsychiatry-focused company pursuing a non-traditional mechanism (psychedelics) in depression.
- Mind Medicine (MindMed): Clinical-stage neuropsychiatry company developing psychedelic-inspired therapies (e.g., MM-120 for GAD) and other CNS candidates. Closely comparable to Seaport as a clinical-stage biotech targeting generalized anxiety disorder and depression with novel mechanisms.
Broad incumbents
- Acadia Pharmaceuticals: Established commercial-stage CNS biopharma with Nuplazid (pimavanserin) for Parkinson's disease psychosis and a growing pipeline in CNS indications. Comparable as a larger, more established player in the broader CNS specialty space with overlapping commercial dynamics.
- Cerevel Therapeutics: CNS-focused biopharma developing therapies for schizophrenia, Parkinson's, and epilepsy (now part of AbbVie following acquisition). Comparable as a once-independent CNS specialist with a pipeline of differentiated neuroscience candidates that ultimately validated through large-pharma acquisition.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat4 records
Key risks6 records
Key highlights6 records
Customer concentration
Seaport Therapeutics social profiles
Digital presenceSeaport Therapeutics financial estimates
Financial estimateRevenue estimate
Valuation estimate
Seaport Therapeutics leadership team
Management profileNumber of profiles
Profiles14 records
Seaport Therapeutics funding detail
Funding detailFunding overview
Funding rounds3 records
Investors12 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Seaport Therapeutics M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Seaport Therapeutics
What does Seaport Therapeutics do?
Seaport Therapeutics is a clinical-stage biopharmaceutical company developing oral neuropsychiatric medicines using its proprietary Glyph™ lymphatic-targeting prodrug platform. The company's lead programs are GlyphAllo (SPT-300) for major depressive disorder and GlyphAgo (SPT-320) for generalized anxiety disorder, with additional pipeline candidates in pre-clinical development. Products are investigational, have not yet received regulatory approval, and are not generating revenue.
Is Seaport Therapeutics a public or private company?
Seaport Therapeutics is a public company. It is classified as public and is currently operating.
When was Seaport Therapeutics founded?
Seaport Therapeutics was founded in 2024. It employs 51 to 100 people.
Where is Seaport Therapeutics based?
Seaport Therapeutics is headquartered in Boston, United States, in the North America region.
How does Seaport Therapeutics make money?
One revenue line is on record: pharmaceutical Product Sales.
Who are Seaport Therapeutics's main competitors?
Direct peers on record are Karuna Therapeutics, Sage Therapeutics, Axsome Therapeutics and Intra-Cellular Therapies. Emerging players are Neumora Therapeutics, Praxis Precision Medicines, Compass Pathways and Mind Medicine (MindMed). Broad incumbents are Acadia Pharmaceuticals and Cerevel Therapeutics.
Does Seaport Therapeutics have an API?
No public API is recorded for Seaport Therapeutics.
What industry is Seaport Therapeutics in?
Seaport Therapeutics's product category is Clinical-stage neuropsychiatric pharmaceuticals. Its primary akta.pro industry code is HLAIAIAD, Rare Neurology & Neurodegenerative Disorder Therapies. Its NAICS code is 5417 and its SIC code is 2834.